Animas closes $10m purchase of Cygnus:
This article was originally published in Clinica
West Chester, Pennsylvania insulin infusion pump maker Animas has completed its asset purchase from Cygnus. The $10m cash deal, which was announced in December 2004, brings Animas electrochemical sensor continuous blood glucose monitoring technology, which Cygnus had commercialised as the GlucoWatch Biographer device. This product had a tendency to cause skin irritation. After the breakdown of a distribution deal with Sankyo, Cygnus shareholders agreed to the company's dissolution. Animas intends to replace GlucoWatch's reverse electro-iontophoresis procedure for extracting glucose molecules with micro-needle technology it recently exclusively licensed from Debiotech.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.